The immunocytokine NHS-IL12 as a potential cancer therapeutic

被引：0
|
作者：
Fallon, Jonathan K. [1 ]
Tighe, Robert [2 ]
Lyon, Amanda J. [1 ]
Sabzevari, Helen [2 ]
Schlom, Jeffrey [1 ]
Greiner, John W. [1 ]
机构：
[1] NCI, Bethesda, MD 20892 USA
[2] EMD Serono, Billerica, MA USA
来源：
CANCER RESEARCH | 2014年 / 74卷 / 19期
关键词：
D O I：
10.1158/1538-7445.AM2014-2573
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2573
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Immune-mediated mechanisms involved in the synergistic anti-tumor efficacy of NHS-IL12 combined with the class I HDAC inhibitor entinostat
    Hicks, Kristin
    Ozawa, Yohei
    Knudson, Karin
    Schlom, Jeffrey
    Gameiro, Sofia
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [22] Improved intratumoral penetration of IL12 immunocytokine enhances the antitumor efficacy
    Jung, Keunok
    Yoo, Sojung
    Kim, Jung-Eun
    Kim, Wook
    Kim, Yong-Sung
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [23] CDK12: a potential therapeutic target in cancer
    Emadi, Fatemeh
    Teo, Theodosia
    Rahaman, Muhammed H.
    Wang, Shudong
    DRUG DISCOVERY TODAY, 2020, 25 (12) : 2257 - 2267
  • [24] Phase Ib, open-label, dose-escalation study of M9241 (NHS-IL12) plus avelumab in patients (pts) with advanced solid tumours
    Strauss, J.
    Vugmeyster, Y.
    Sznol, M.
    Pachynski, R. K.
    Trang, K.
    Chennoufi, S.
    Gulley, J. L.
    ANNALS OF ONCOLOGY, 2019, 30
  • [25] Combining IL-12 immunocytokine (M9241) with docetaxel in metastatic prostate cancer: A phase I study.
    Atiq, Mohammad O.
    Chandran, Elias Bin Aris
    Meininger, Luke
    Karzai, Fatima
    Bilusic, Marijo
    Marte, Jennifer L.
    Arlen, Philip M.
    Cordes, Lisa M.
    Strauss, Julius
    Redman, Jason
    Floudas, Charalampos S.
    Pastor, Danielle M.
    Owens, Helen
    Hankin, Amy
    Williams, Monique
    Figg, William Douglas
    Dahut, William L.
    Schlom, Jeffrey
    Gulley, James L.
    Madan, Ravi Amrit
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E17033 - E17033
  • [26] IL-12 family cytokines and autoimmune diseases: A potential therapeutic target?
    Cui, Xiaoyu
    Liu, Wu
    Jiang, Hanxue
    Zhao, Qihan
    Hu, Yuehong
    Tang, Xinyue
    Liu, Xianli
    Dai, Haoran
    Rui, Hongliang
    Liu, Baoli
    JOURNAL OF TRANSLATIONAL AUTOIMMUNITY, 2025, 10
  • [27] IL-12/IL-23 pathway inhibition has therapeutic potential in Alzheimer disease
    Nature Reviews Neurology, 2013, 9 (2) : 61 - 61
  • [28] Therapeutic efficacy of the F8-IL2 immunocytokine in a metastatic mouse model of lung adenocarcinoma
    Wieckowski, Sebastien
    Hemmerle, Teresa
    Prince, Spasenja Savic
    Schlienger, Beatrice Dolder
    Hillinger, Sven
    Neri, Dario
    Zippelius, Alfred
    LUNG CANCER, 2015, 88 (01) : 9 - 15
  • [29] An engineered immunocytokine with collagen affinity improves the tumor bioavailability, tolerability, and therapeutic efficacy of IL-2
    Silver, Aliyah B.
    Tzeng, Stephany Y.
    Lager, Mallory
    Wang, Jeremy
    Ishihara, Jun
    Green, Jordan J.
    Spangler, Jamie B.
    CELL REPORTS MEDICINE, 2023, 4 (11)
  • [30] A phase I study of bintrafusp alfa and NHS-IL12 (M9241) alone and in combination with stereotactic body radiation therapy (SBRT) in patients with metastatic genitourinary (GU) malignancies.
    Simon, Nicholas I.
    Niglio, Scot Anthony
    Chandran, Elias
    Iannantuono, Giovanni Maria
    Boudjadi, Salah
    Banday, Rouf
    Girardi, Daniel da Motta
    Cordes, Lisa M.
    Ley, Lisa
    Gurram, Sandeep
    Kydd, Andre Rashad
    Jones, Jennifer C.
    Salerno, Kilian Elizabeth
    Patel, Krishnan
    Valera, Vladimir
    Parnes, Howard L.
    Figg, William Douglas
    Gulley, James L.
    Schlom, Jeffrey
    Apolo, Andrea B.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345